Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProBactrix in GERD
NCT00324532Phase 3Completed
- Sponsor
- Bio Balance, Inc.
- Start
- May 2006
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Escherichia coli strain M17 in gastroesophageal reflux disease (GERD), sponsored by Bio Balance, Inc. Primary endpoint: Improvement in one or more GI symptoms. Started May 2006; status: completed.
02
Drugs
Escherichia coli strain M17
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00324532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324532.